NIH-backed research reveals that a simple skin test may revolutionize early diagnosis of Parkinson’s and related neurodegenerative disorders.
NIH-backed research reveals that a simple skin test may revolutionize early diagnosis of Parkinson’s and related neurodegenerative disorders.
The biotech firm discontinues its ReFocus-ALZ and ReThink-ALZ trials, marking a major shift in its neurodegenerative disease strategy.
Amgen’s MariTide leads the pack, while other candidates face setbacks in the competitive GLP-1RA landscape.
New molecular imaging techniques show promise in improving cancer surgery precision and outcomes.
Gilead’s twice-yearly injectable PrEP shows near-perfect efficacy, prompting global access initiatives and a rethinking of HIV prevention strategies.
On November 13, 2024, the U.S. Food and Drug Administration (FDA) approved a novel gene therapy for aromatic …
Facing partnership setbacks and pipeline pressure, Editas Medicine lays off 65% of its staff and pivots toward its …
In a surprising move, Novartis snapped up preclinical-stage Kate Therapeutics for over a billion dollars—signaling renewed confidence in …
From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
Exploring recent advancements in CRISPR therapies, personalized gene editing, and artificial intelligence transforming drug development and clinical trials.
Already a subscriber? Log in